BRAIN BIOTECH AG (BNN.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:BNN • DE0005203947

2.32 EUR

+0.03 (+1.31%)

Last: Jan 30, 2026, 07:00 PM

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to BNN. BNN was compared to 71 industry peers in the Chemicals industry. BNN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BNN has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BNN has reported negative net income.
In the past year BNN has reported a negative cash flow from operations.
BNN had negative earnings in each of the past 5 years.
In the past 5 years BNN always reported negative operating cash flow.

1.2 Ratios

BNN has a worse Return On Assets (-16.14%) than 84.51% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.14%
ROE	N/A
ROIC	N/A

ROA(3y)-10.89%

ROA(5y)-10.5%

ROE(3y)-49.48%

ROE(5y)-41.57%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BNN's Gross Margin of 57.11% is amongst the best of the industry. BNN outperforms 87.32% of its industry peers.
In the last couple of years the Gross Margin of BNN has remained more or less at the same level.
BNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	57.11%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.53%

GM growth 5Y-0.08%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNN remains at a similar level compared to 1 year ago.
The number of shares outstanding for BNN has been increased compared to 5 years ago.
Compared to 1 year ago, BNN has an improved debt to assets ratio.

2.2 Solvency

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	N/A

ROIC/WACCN/A

WACC6.91%

2.3 Liquidity

A Current Ratio of 2.39 indicates that BNN has no problem at all paying its short term obligations.
BNN's Current ratio of 2.39 is fine compared to the rest of the industry. BNN outperforms 77.46% of its industry peers.
A Quick Ratio of 2.39 indicates that BNN has no problem at all paying its short term obligations.
BNN's Quick ratio of 2.39 is amongst the best of the industry. BNN outperforms 91.55% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.39
Quick Ratio	2.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BNN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.27%.
The Revenue has decreased by -4.71% in the past year.
The Revenue has been growing slightly by 6.74% on average over the past years.

EPS 1Y (TTM)-33.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%76.38%

Revenue 1Y (TTM)-4.71%

Revenue growth 3Y12.27%

Revenue growth 5Y6.74%

Sales Q2Q%0.7%

3.2 Future

Based on estimates for the next years, BNN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.62% on average per year.
Based on estimates for the next years, BNN will show a small growth in Revenue. The Revenue will grow by 5.09% on average per year.

EPS Next Y31.93%

EPS Next 2Y15.97%

EPS Next 3Y37.03%

EPS Next 5Y28.62%

Revenue Next Year-0.63%

Revenue Next 2Y5.77%

Revenue Next 3Y6.99%

Revenue Next 5Y5.09%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNN. In the last year negative earnings were reported.
Also next year BNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.